

Blood-Brain Barrier Transport Drugs-United States Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/BE013576404EN.html>

Date: February 2018

Pages: 144

Price: US\$ 3,480.00 (Single User License)

ID: BE013576404EN

Abstracts

Report Summary

Blood-Brain Barrier Transport Drugs-United States Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Blood-Brain Barrier Transport Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole United States and Regional Market Size of Blood-Brain Barrier Transport Drugs 2013-2017, and development forecast 2018-2023

Main market players of Blood-Brain Barrier Transport Drugs in United States, with company and product introduction, position in the Blood-Brain Barrier Transport Drugs market

Market status and development trend of Blood-Brain Barrier Transport Drugs by types and applications

Cost and profit status of Blood-Brain Barrier Transport Drugs, and marketing status

Market growth drivers and challenges

The report segments the United States Blood-Brain Barrier Transport Drugs market as:

United States Blood-Brain Barrier Transport Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

New England

The Middle Atlantic

The Midwest

The West

The South

Southwest

United States Blood-Brain Barrier Transport Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Carrier-mediated Transport

Receptor-mediated Transport

Absorptive-mediated Transport

Active Efflux Transport

Others

United States Blood-Brain Barrier Transport Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Alzheimer's Disease

Epilepsy

Parkinson's Disease

Multiple Sclerosis

Hunter's Syndrome

Brain Cancer

Others

United States Blood-Brain Barrier Transport Drugs Market: Players Segment Analysis (Company and Product introduction, Blood-Brain Barrier Transport Drugs Sales Volume, Revenue, Price and Gross Margin):

Cyclenium

BioAdvance

EIP Pharma

Bioasis

Immune Pharmaceuticals

AZ Therapies

Palobiofarma

Bach Pharma
BrainsGate
CarThera
Dainippon Sumitomo Pharma
Fluorinov Pharma
Fondazione Telethon
Minoryx
NewGen Therapeutics

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF BLOOD-BRAIN BARRIER TRANSPORT DRUGS

- 1.1 Definition of Blood-Brain Barrier Transport Drugs in This Report
- 1.2 Commercial Types of Blood-Brain Barrier Transport Drugs
 - 1.2.1 Carrier-mediated Transport
 - 1.2.2 Receptor-mediated Transport
 - 1.2.3 Absorptive-mediated Transport
 - 1.2.4 Active Efflux Transport
 - 1.2.5 Others
- 1.3 Downstream Application of Blood-Brain Barrier Transport Drugs
 - 1.3.1 Alzheimer's Disease
 - 1.3.2 Epilepsy
 - 1.3.3 Parkinson's Disease
 - 1.3.4 Multiple Sclerosis
 - 1.3.5 Hunter's Syndrome
 - 1.3.6 Brain Cancer
 - 1.3.7 Others
- 1.4 Development History of Blood-Brain Barrier Transport Drugs
- 1.5 Market Status and Trend of Blood-Brain Barrier Transport Drugs 2013-2023
 - 1.5.1 United States Blood-Brain Barrier Transport Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Blood-Brain Barrier Transport Drugs Market Status and Trend 2013-2023

CHAPTER 2 UNITED STATES MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Blood-Brain Barrier Transport Drugs in United States 2013-2017
- 2.2 Consumption Market of Blood-Brain Barrier Transport Drugs in United States by Regions
 - 2.2.1 Consumption Volume of Blood-Brain Barrier Transport Drugs in United States by Regions
 - 2.2.2 Revenue of Blood-Brain Barrier Transport Drugs in United States by Regions
- 2.3 Market Analysis of Blood-Brain Barrier Transport Drugs in United States by Regions
 - 2.3.1 Market Analysis of Blood-Brain Barrier Transport Drugs in New England 2013-2017
 - 2.3.2 Market Analysis of Blood-Brain Barrier Transport Drugs in The Middle Atlantic 2013-2017

2.3.3 Market Analysis of Blood-Brain Barrier Transport Drugs in The Midwest
2013-2017

2.3.4 Market Analysis of Blood-Brain Barrier Transport Drugs in The West 2013-2017

2.3.5 Market Analysis of Blood-Brain Barrier Transport Drugs in The South 2013-2017

2.3.6 Market Analysis of Blood-Brain Barrier Transport Drugs in Southwest 2013-2017

2.4 Market Development Forecast of Blood-Brain Barrier Transport Drugs in United
States 2018-2023

2.4.1 Market Development Forecast of Blood-Brain Barrier Transport Drugs in United
States 2018-2023

2.4.2 Market Development Forecast of Blood-Brain Barrier Transport Drugs by
Regions 2018-2023

CHAPTER 3 UNITED STATES MARKET STATUS AND FORECAST BY TYPES

3.1 Whole United States Market Status by Types

3.1.1 Consumption Volume of Blood-Brain Barrier Transport Drugs in United States by
Types

3.1.2 Revenue of Blood-Brain Barrier Transport Drugs in United States by Types

3.2 United States Market Status by Types in Major Countries

3.2.1 Market Status by Types in New England

3.2.2 Market Status by Types in The Middle Atlantic

3.2.3 Market Status by Types in The Midwest

3.2.4 Market Status by Types in The West

3.2.5 Market Status by Types in The South

3.2.6 Market Status by Types in Southwest

3.3 Market Forecast of Blood-Brain Barrier Transport Drugs in United States by Types

CHAPTER 4 UNITED STATES MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

4.1 Demand Volume of Blood-Brain Barrier Transport Drugs in United States by
Downstream Industry

4.2 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry in
Major Countries

4.2.1 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry
in New England

4.2.2 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry
in The Middle Atlantic

4.2.3 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry

in The Midwest

4.2.4 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry in The West

4.2.5 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry in The South

4.2.6 Demand Volume of Blood-Brain Barrier Transport Drugs by Downstream Industry in Southwest

4.3 Market Forecast of Blood-Brain Barrier Transport Drugs in United States by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF BLOOD-BRAIN BARRIER TRANSPORT DRUGS

5.1 United States Economy Situation and Trend Overview

5.2 Blood-Brain Barrier Transport Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 BLOOD-BRAIN BARRIER TRANSPORT DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN UNITED STATES

6.1 Sales Volume of Blood-Brain Barrier Transport Drugs in United States by Major Players

6.2 Revenue of Blood-Brain Barrier Transport Drugs in United States by Major Players

6.3 Basic Information of Blood-Brain Barrier Transport Drugs by Major Players

6.3.1 Headquarters Location and Established Time of Blood-Brain Barrier Transport Drugs Major Players

6.3.2 Employees and Revenue Level of Blood-Brain Barrier Transport Drugs Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 BLOOD-BRAIN BARRIER TRANSPORT DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Cyclenium

7.1.1 Company profile

7.1.2 Representative Blood-Brain Barrier Transport Drugs Product

7.1.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Cyclenium

7.2 BioAdvance

7.2.1 Company profile

7.2.2 Representative Blood-Brain Barrier Transport Drugs Product

7.2.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of BioAdvance

7.3 EIP Pharma

7.3.1 Company profile

7.3.2 Representative Blood-Brain Barrier Transport Drugs Product

7.3.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of EIP Pharma

7.4 Bioasis

7.4.1 Company profile

7.4.2 Representative Blood-Brain Barrier Transport Drugs Product

7.4.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Bioasis

7.5 Immune Pharmaceuticals

7.5.1 Company profile

7.5.2 Representative Blood-Brain Barrier Transport Drugs Product

7.5.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Immune Pharmaceuticals

7.6 AZ Therapies

7.6.1 Company profile

7.6.2 Representative Blood-Brain Barrier Transport Drugs Product

7.6.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of AZ Therapies

7.7 Palobiofarma

7.7.1 Company profile

7.7.2 Representative Blood-Brain Barrier Transport Drugs Product

7.7.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Palobiofarma

7.8 Bach Pharma

7.8.1 Company profile

7.8.2 Representative Blood-Brain Barrier Transport Drugs Product

7.8.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Bach Pharma

7.9 BrainsGate

7.9.1 Company profile

- 7.9.2 Representative Blood-Brain Barrier Transport Drugs Product
- 7.9.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of BrainsGate
- 7.10 CarThera
 - 7.10.1 Company profile
 - 7.10.2 Representative Blood-Brain Barrier Transport Drugs Product
 - 7.10.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of CarThera
- 7.11 Dainippon Sumitomo Pharma
 - 7.11.1 Company profile
 - 7.11.2 Representative Blood-Brain Barrier Transport Drugs Product
 - 7.11.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Dainippon Sumitomo Pharma
- 7.12 Fluorinov Pharma
 - 7.12.1 Company profile
 - 7.12.2 Representative Blood-Brain Barrier Transport Drugs Product
 - 7.12.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Fluorinov Pharma
- 7.13 Fondazione Telethon
 - 7.13.1 Company profile
 - 7.13.2 Representative Blood-Brain Barrier Transport Drugs Product
 - 7.13.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Fondazione Telethon
- 7.14 Minoryx
 - 7.14.1 Company profile
 - 7.14.2 Representative Blood-Brain Barrier Transport Drugs Product
 - 7.14.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of Minoryx
- 7.15 NewGen Therapeutics
 - 7.15.1 Company profile
 - 7.15.2 Representative Blood-Brain Barrier Transport Drugs Product
 - 7.15.3 Blood-Brain Barrier Transport Drugs Sales, Revenue, Price and Gross Margin of NewGen Therapeutics

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BLOOD-BRAIN BARRIER TRANSPORT DRUGS

- 8.1 Industry Chain of Blood-Brain Barrier Transport Drugs
- 8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF BLOOD-BRAIN BARRIER TRANSPORT DRUGS

9.1 Cost Structure Analysis of Blood-Brain Barrier Transport Drugs

9.2 Raw Materials Cost Analysis of Blood-Brain Barrier Transport Drugs

9.3 Labor Cost Analysis of Blood-Brain Barrier Transport Drugs

9.4 Manufacturing Expenses Analysis of Blood-Brain Barrier Transport Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF BLOOD-BRAIN BARRIER TRANSPORT DRUGS

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Blood-Brain Barrier Transport Drugs-United States Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/BE013576404EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BE013576404EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

